Research investment accelerated
Marinova has expanded its research investment in 2026 by undertaking additional research projects across Australia. Read more
Latest news
Exploring norovirus inhibition
A recent in vitro investigation has evaluated the potential of fucoidans, along with the polysaccharide ulvan, to inhibit norovirus virus-like particles binding to histo-blood group antigens in human saliva. Read more
Introducing Marinova's Technical Services Manager
This brief interview provides insight into the role of Marinova's Technical Services Manager, Mr David Gesch. Read more
Exploring cancer nanomedicine
A recent in vitro study screened fucoidans for anti-angiogenic activity and subsequently incorporated them into nanoparticles. Read more
2026 trade show schedule
Marinova will be exhibiting at a number of international trade events throughout 2026. Read more